Literature DB >> 2661481

5-Fluorouracil containing combinations in murine tumor systems.

T H Corbett1, M C Bissery, P Mucci-LoRusso, L Polin.   

Abstract

5-FUra is a familiar member of a variety of clinically useful regimens. Examples include: Cytoxan-Adriamycin-5-FUra (CAF); Methotrexate-Prednisone-Vincristine-Cytoxan-5-FUra (the Cooper regimen); and CisDDPt-5-FUra. In addition to its clinical utility, over 20 different 5-FUra-combinations have been reported to be therapeutically synergistic in experimental systems. In this report, we will attempt to evaluate the reasons behind the widespread utility of this agent in combination therapy and suggest future directions for research efforts.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2661481     DOI： 10.1007/bf00178190

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  22 in total

1.  Uptake and binding of vincristine by murine leukemia cells.

Authors:  W A Bleyer; S A Frisby; V T Oliverio
Journal:  Biochem Pharmacol       Date:  1975-03-01       Impact factor: 5.858

Review 2.  Is the P388 murine tumor no longer adequate as a drug discovery model?

Authors:  T H Corbett; F A Valeriote; L H Baker
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

3.  Mechanism of cellular drug resistance.

Authors:  H B Bosmann
Journal:  Nature       Date:  1971-10-22       Impact factor: 49.962

4.  In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.

Authors:  R K Johnson; M P Chitnis; W M Embrey; E B Gregory
Journal:  Cancer Treat Rep       Date:  1978-10

5.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

Authors:  T H Corbett; B J Roberts; W R Leopold; J C Peckham; L J Wilkoff; D P Griswold; F M Schabel
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

6.  Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.

Authors:  T H Corbett; M C Bissery; A Wozniak; J Plowman; L Polin; E Tapazoglou; J Dieckman; F Valeriote
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

7.  Correlations between anthracycline resistance, drug accumulation and membrane glycoprotein patterns in solid tumors of mice.

Authors:  D Kessel; T Corbett
Journal:  Cancer Lett       Date:  1985-09-15       Impact factor: 8.679

8.  Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in a murine model.

Authors:  R Pazdur; B G Redman; T Corbett; M Phillips; L H Baker
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

9.  Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy.

Authors:  T H Corbett; D P Griswold; B J Roberts; J C Peckham; F M Schabel
Journal:  Cancer Treat Rep       Date:  1978-10

Review 10.  Establishment of cross-resistance profiles for new agents.

Authors:  F M Schabel; H E Skipper; M W Trader; W R Laster; D P Griswold; T H Corbett
Journal:  Cancer Treat Rep       Date:  1983-10
View more
  4 in total

1.  Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice.

Authors:  L Polin; F Valeriote; K White; C Panchapor; S Pugh; J Knight; P LoRusso; M Hussain; E Liversidge; N Peltier; T Golakoti; G Patterson; R Moore; T H Corbett
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice.

Authors:  Lisa Polin; Kathryn White; Juiwanna Kushner; Jennifer Paluch; Chiab Simpson; Susan Pugh; Matthew K Edelstein; Stuart Hazeldine; Joseph Fontana; Patricia LoRusso; Jerome P Horwitz; Thomas H Corbett
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

3.  Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.

Authors:  Jian Liang; Richard E Moore; Eric D Moher; John E Munroe; Rima S Al-awar; David A Hay; David L Varie; Tony Y Zhang; James A Aikins; Michael J Martinelli; Chuan Shih; James E Ray; Lowell L Gibson; Vasu Vasudevan; Lisa Polin; Kathryn White; Juiwanna Kushner; Chiab Simpson; Susan Pugh; Thomas H Corbett
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

4.  Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169.

Authors:  Thomas H Corbett; Kathryn White; Lisa Polin; Juiwanna Kushner; Jennifer Paluch; Chuan Shih; Cora Sue Grossman
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.